DK1740945T3 - Kke-invasive, in-vitro funktionele vævspøvesystemer - Google Patents

Kke-invasive, in-vitro funktionele vævspøvesystemer Download PDF

Info

Publication number
DK1740945T3
DK1740945T3 DK05730755.5T DK05730755T DK1740945T3 DK 1740945 T3 DK1740945 T3 DK 1740945T3 DK 05730755 T DK05730755 T DK 05730755T DK 1740945 T3 DK1740945 T3 DK 1740945T3
Authority
DK
Denmark
Prior art keywords
cells
cell
assay
tissue
vol
Prior art date
Application number
DK05730755.5T
Other languages
English (en)
Inventor
Heribert Bohlen
Eugen Kolossov
Ralf Kettenhofen
Melanie Scholz
Leo Fink
Original Assignee
Ncardia Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ncardia Ag filed Critical Ncardia Ag
Application granted granted Critical
Publication of DK1740945T3 publication Critical patent/DK1740945T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G01N33/4836—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures using multielectrode arrays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • G01N33/5438—Electrodes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (19)

1. Funktionel in-vitro-celle- og vævsassayfremgangsmåde til at tilvejebringe og / eller at profilere en forbindelse af interesse, der omfatter: (a) at dyrke et biologisk materiale omfattende celler, et celleaggregat, væv eller et organ på et elektrodearray; (b) at underkaste det biologiske materiale for et teststof; og (c) at måle elektrisk aktivitet af det biologiske materiale gennem elek-trodearrayet og at analysere en eller alle af de følgende parametre: (i) Na+-kanaler; (ii) Ca2+-/ K+-kanaler; (iii) K+-kanaler; (iv) amplitude og / eller feltpotentialevarighed (FDP); (v) hjertecellekronotropi eller nervecellers affyringsperioder; (vi) arytmier, EAD-lignende fænomener; (vii) pH-værdi (viii) partialtryk af ilt (pO2); (ix) slagstop og / eller (x) analyse af AV-dissociationskontraktilitet, NO-virkninger og / eller morfologiske ændringer; hvor cellerne, celleaggregatet, vævet og organet tilvejebringes fra stamceller, der er genetisk forandret, til at omfatte en selekterbar markør, der er operativt forbundet til en første celletypespecifik regulatorisk sekvens, der er specifik for den første celletype og differentieret og udtømt af forholdsvis udifferentierede celler og / eller uønskede celletyper ved anvendelse af et selektionssystem, der er dødeligt for de uønskede celler og celletyper ved at udtrykke et selekterbart markørgen, der gør celler af specifik celletyper resistente over for den dødelige effekt.
2. Assay ifølge krav 1, hvor stamcellerne er embryonale stamceller (ES).
3. Assay ifølge krav 2, hvor det biologiske materiale er væv eller vævlignende strukturer tilvejebragt ved dyrkning af en ES afledt første celle- type, under tilstedeværelse af mindst en embryonisk anden celletype.
4. Assay ifølge ethvert af kravene 1 til 3, hvor den selekterbare markør giver resistens overfor puromycin, neomycin eller hygromycin.
5. Assay ifølge ethvert af kravene 3 til 4, hvor den embryonale stamcelle af den første celletype af embryonale stamceller yderligere omfatter et reportergen, der er operativt forbundet med en celletypespecifik regulatorisk sekvens, der er specifik for den første celletype.
6. Assay ifølge krav 5, hvor den celletypespecifikke regulatoriske sekvens af reportergenet er i det væsentlige den samme som den første celletypespecifikke regulatoriske sekvens af markørgenet.
7. Assay ifølge ethvert af kravene 1 til 6, hvor det biologiske materiale omfatter kardiomyocytter.
8. Assay ifølge ethvert af kravene 1 til 7, hvor celleaggregaterne er embryoide legemer (EB’er).
9. Assay ifølge ethvert af kravene 1 til 8, hvor elektrodearrayet er et multi- eller mikroelektrodearray (MEA).
10. Assay ifølge ethvert af kravene 1 til 9, hvor elektrodearrayet er overtrukket med fibronectin.
11. Assay ifølge ethvert af kravene 1 til 10, hvor mindst kronotropi af hjerteceller eller AV-dissociationskontraktilitet analyseres.
12. Assay ifølge ethvert af kravene 1 til 11, hvor det biologiske materiale omfatter embryoide legemer (EB’er), hvor EB'erne består af funktionelt hjertevæv, der bevæger sig autonomt og dækker elektrofysiologiske egenskaber af atrielle og / eller ventrikulære kardiomyocytter, såvel som af pacemakerceller.
13. Assay ifølge ethvert af kravene 1 til 12, hvor det biologiske materiale helt eller delvist er afledt af en murin ES-cellelinie.
14. Assay ifølge ethvert af kravene 1 til 13, hvor det biologiske materiale omfatter en eller flere celler, der er genetisk manipuleret til at (over)udtrykke eller inhibere udtryk af et målgen.
15. Assay ifølge ethvert af kravene 1 til 14, hvor en forbindelse kendt for at aktivere eller inhibere fremgangsmåde til differentiering og / eller vævs strukturdannelse er tilsat til dyrkningsmediet.
16. Anvendelse af et kit til at udføre en assay ifølge ethvert af kravene 1 til 15, hvor kittet indeholder en vektor eller en sammensætning af vektorer, en multi- eller pluripotent celle; og kulturmedium, rekombinante nukleinsy-remolekyler, array og / eller standardforbindelser.
17. Anvendelse af en chip omfattende et elektrodearray og celler som defineret i ethvert af kravene 1 til 15 til at udføre en assay ifølge ethvert af kravene 1 til 15.
18. Anvendelse af et apparat til analyse af elektrodearrayet i assayen ifølge ethvert af kravene 1 til 15.
19. Anvendelse af stamceller, celleaggregater, et væv, vektor eller sammensætning af vektorer, et array, et apparat eller en chip i en assay ifølge ethvert af kravene 1 til 15.
DK05730755.5T 2004-04-07 2005-04-07 Kke-invasive, in-vitro funktionele vævspøvesystemer DK1740945T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04008497 2004-04-07
PCT/EP2005/003662 WO2005098425A1 (en) 2004-04-07 2005-04-07 Non-invasive, in vitro functional tissue assay systems

Publications (1)

Publication Number Publication Date
DK1740945T3 true DK1740945T3 (da) 2019-01-21

Family

ID=34964061

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05730755.5T DK1740945T3 (da) 2004-04-07 2005-04-07 Kke-invasive, in-vitro funktionele vævspøvesystemer

Country Status (7)

Country Link
US (3) US9945840B2 (da)
EP (1) EP1740945B1 (da)
JP (1) JP5074921B2 (da)
CA (1) CA2560334A1 (da)
DK (1) DK1740945T3 (da)
ES (1) ES2701704T3 (da)
WO (1) WO2005098425A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2701704T3 (es) 2004-04-07 2019-02-25 Ncardia Ag Sistemas de ensayo tisulares funcionales no invasivos in vitro
ES2770067T3 (es) 2004-05-11 2020-06-30 Ncardia Ag Descubrimiento de fármacos basado en células diferenciadas in vitro
WO2007120699A2 (en) 2006-04-10 2007-10-25 Wisconsin Alumni Research Foundation Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds & other chemicals
WO2008152983A1 (ja) 2007-06-08 2008-12-18 National University Corporation Tokyo Medical And Dental University モデル細胞チップ、モデル細胞チップによる薬効評価装置、および薬効評価方法
FR2937050A1 (fr) * 2008-10-10 2010-04-16 Inst Curie Dispositif de culture cellulaire
EP2218772A1 (en) 2009-02-09 2010-08-18 Koninklijke Philips Electronics N.V. Cardiomyocytes-containing device and method for manufacturing the same
JP5544474B2 (ja) * 2009-12-11 2014-07-09 国立大学法人東北大学 細胞検査用バイオアッセイ用キット
EP2383576B1 (en) * 2010-04-28 2013-04-03 Imec Micro-electrode grid array for top and bottom recording from samples
EP2580317B1 (en) * 2010-06-13 2020-12-23 Institute of Biophysics Chinese Academy of Sciences Methods and compositions for preparing cardiomyocytes from stem cells and uses thereof
JP6151644B2 (ja) * 2011-03-03 2017-06-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 操作装置、堆積方法、注入方法、検出装置及び検出方法
US9099436B2 (en) * 2012-03-29 2015-08-04 California Institute Of Technology Sensor probe for bio-sensing and chemical-sensing applications
CA2886396C (en) 2012-07-23 2023-08-22 Institute Of Biophysics, Chinese Academy Of Sciences Method for inducing pluripotent stem cells to differentiate into ventricular cardiomyocytes in vitro
US9279801B2 (en) * 2013-07-26 2016-03-08 Axion Biosystems, Inc. Devices, systems and methods for high-throughput electrophysiology
DE102014203280B4 (de) * 2014-02-24 2015-12-17 Cytocentrics Bioscience Gmbh Vorrichtung zur Bestimmung von Messgrößen an Membranen
DE102014003432B3 (de) * 2014-03-11 2015-05-07 NeuroProof GmbH Verfahren zum Testen neuroaktiver Substanzen
WO2016025646A1 (en) 2014-08-12 2016-02-18 Axion Biosystems, Inc. Cell-based biosensor array and associated methods for manufacturing the same
US11022605B2 (en) 2016-08-26 2021-06-01 University Of Central Florida Research Foundation, Inc. Multi-component in vitro system to deduce cell signaling pathways by electronic stimulation patterns
GB201818885D0 (en) * 2018-11-20 2019-01-02 Precomb Therapeutics Ag 3d human cancer model-based combinatiorial drug development method
TWI810565B (zh) * 2021-05-14 2023-08-01 國立清華大學 可攜式觀察微流道用環型螢光光路系統及其運作方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299439C (da)
US6072402A (en) 1992-01-09 2000-06-06 Slc Technologies, Inc. Secure entry system with radio communications
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
USRE37979E1 (en) 1989-09-29 2003-02-04 Mitsubishi Chemical Corporation Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof
DD299439B5 (de) 1990-05-11 1995-10-19 Inst Pflanzengenetik & Kultur Verfahren zur Untersuchung der Wirkung von chemischen Wirkstoffen und medizinisch-pharmazeutischen Praeparaten
GB9308271D0 (en) 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
KR960705209A (ko) 1993-09-10 1996-10-09 잭 엠. 그랜노위츠 녹색 형광 단백의 용도
US5602301A (en) 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
US6015671A (en) 1995-06-07 2000-01-18 Indiana University Foundation Myocardial grafts and cellular compositions
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
DE4441327C1 (de) 1994-11-22 1995-11-09 Inst Pflanzengenetik & Kultur Embryonale Herzmuskelzellen, ihre Herstellung und ihre Verwendung
US5641644A (en) 1994-12-09 1997-06-24 Board Of Regents, The University Of Texas System Method and apparatus for the precise positioning of cells
GB9504446D0 (en) 1995-03-06 1995-04-26 Medical Res Council Improvements in or relating to gene expression
GB9505663D0 (en) 1995-03-21 1995-05-10 Stringer Bradley M J Genetically modified neural cells
JP2001512316A (ja) 1997-02-13 2001-08-21 メモリアル・スローンケタリング・キャンサー・センター 細胞微環境における変化を光学的に検出する混成分子
JPH10292688A (ja) 1997-02-20 1998-11-04 Kouji Kagetani 扉の施解錠方法
GB9708526D0 (en) 1997-04-25 1997-06-18 Royal Free Hosp School Med Eukaryotic gene expression cassette and uses thereof
US5981268A (en) * 1997-05-30 1999-11-09 Board Of Trustees, Leland Stanford, Jr. University Hybrid biosensors
DE19727962A1 (de) 1997-07-02 1999-01-14 Juergen Hescheler Fluoreszierende Proteine als zelltypspezifische Reporter
AU9017598A (en) 1997-08-12 1999-03-08 Human Genome Sciences, Inc. Human frezzled-like protein
JP2001520170A (ja) 1997-10-16 2001-10-30 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｎｆ−ａｔ３機能に関連した心肥大動物モデルと治療法
US6080576A (en) 1998-03-27 2000-06-27 Lexicon Genetics Incorporated Vectors for gene trapping and gene activation
DE19843234A1 (de) 1998-09-09 2000-03-23 Inst Pflanzengenetik & Kultur Differenzierte Herzzellen mit pathologischen Merkmalen als in vitro-Modell für Herzerkrankungen
GB2342003A (en) 1998-09-21 2000-03-29 Riva Limited Telephone apparatus for handling anonymous calls
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
GB2344670B (en) 1998-12-12 2003-09-03 Ibm System, apparatus and method for controlling access
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
JP2002541832A (ja) 1999-04-21 2002-12-10 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ガレクチン１１
JP2001054883A (ja) 1999-08-11 2001-02-27 Hitachi Koki Co Ltd 電動工具
AU6794700A (en) 1999-08-20 2001-03-19 Board Of Regents, The University Of Texas System Methods and compositions relating to hdac 4 and 5 regulation of cardiac gene expression
DE19962154A1 (de) 1999-12-22 2001-07-12 Medigene Ag Krankhaft veränderte Herzmuskelzelle, ihre Herstellung und Verwendung
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
US20050165612A1 (en) 2000-04-19 2005-07-28 Van Rysselberghe Pierre C. Security systems for delivering goods and services
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
US7256042B2 (en) 2000-04-27 2007-08-14 Geron Corporation Process for making hepatocytes from pluripotent stem cells
IL154159A0 (en) 2000-08-01 2003-07-31 Yissum Res Dev Co Directed differentiation of ebryonic cells
JP2002051782A (ja) 2000-08-09 2002-02-19 Sankyo Co Ltd 骨粗鬆症もしくは関節リウマチの治療または予防剤の試験方法
SE520984C2 (sv) 2000-08-10 2003-09-16 Volvo Technology Corp Metod och system för att låsa upp ett föremål
US7214371B1 (en) 2000-09-01 2007-05-08 Ben-Gurion University Of The Negev Research & Development Authority Tissue engineered biografts for repair of damaged myocardium
US6844184B2 (en) 2000-11-08 2005-01-18 Surface Logix, Inc. Device for arraying biomolecules and for monitoring cell motility in real-time
US20030027331A1 (en) 2000-11-30 2003-02-06 Yan Wen Liang Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
US20040096432A1 (en) 2000-12-27 2004-05-20 Bernd Fleischmann System for the cell-specific and development-specific selection of differentiating embryonic stem cells, adult stem cells and embryonic germline cells
US20040234972A1 (en) 2001-03-20 2004-11-25 Owens Gary K. Method for identifying and purifying smooth muscle progenitor cells
US6836480B2 (en) * 2001-04-20 2004-12-28 International Business Machines Corporation Data structures for efficient processing of multicast transmissions
DE10126371A1 (de) 2001-05-30 2003-02-27 Medigene Ag Verfahren zur Identifizierung von Substanzen gegen Herzmuskelzellen-Hypertrophie
US20030108895A1 (en) 2001-06-25 2003-06-12 Field Loren J. Methods and cell populations for identifying and validating genomic targets, and for drug screening
CA2351156A1 (en) * 2001-07-04 2003-01-04 Peter W. Zandstra A bioprocess for the generation of pluripotent cell derived cells and tissues
EP1412479A4 (en) 2001-07-12 2004-07-28 Geron Corp CELLS WITH CARDIOMYOCYTE GENERATION PRODUCED FROM HUMAN PLURIPOTENT STEM CELLS
GB2394958B (en) 2001-07-24 2006-03-01 Es Cell Int Pte Ltd Methods of inducing differentiation of stem cells
AU2002356043A1 (en) 2001-08-14 2003-03-03 Washington University In St. Louis Systems and methods for screening pharmaceutical chemicals
EP1444326A4 (en) 2001-08-24 2006-06-28 Advanced Cell Tech Inc SCREENING ASSAYS FOR IDENTIFICATION OF AGENTS INDUCING DIFFERENTIATION, AND PRODUCTION OF CELLS DIFFERENTIATED FOR CELL THERAPY
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
MXPA04005010A (es) * 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
US6743962B2 (en) 2002-01-31 2004-06-01 Chevron U.S.A. Inc. Preparation of high octane alkylate from Fischer-Tropsch olefins
CA2385734A1 (en) 2002-03-04 2003-09-04 Board Of Regents, The University Of Texas System Transgenic cardiomyoctes with controlled proliferation and differentiation
EP1485479A2 (en) 2002-03-19 2004-12-15 The University Of Sheffield Stem cell culture
GB2387501A (en) 2002-04-11 2003-10-15 Andrew Nicholas Door intercom system with remote screening/access control via a mobile phone
NZ537245A (en) 2002-07-26 2010-04-30 Wisconsin Alumni Res Found Method of testing cardiomyocytes derived from human embryonic stem cells formed in embryoid bodies differentiated into all of the major cardiac muscle cell types, including ventricular, atrial, and nodal cells
US7627535B2 (en) 2002-12-13 2009-12-01 Newspaper Delivery Technologies, Inc. Method and apparatus for supporting delivery, sale and billing of perishable and time-sensitive goods such as newspapers, periodicals and direct marketing and promotional materials
EP1641912B1 (en) 2003-06-20 2016-04-27 Axiogenesis Ag Tissue modelling in embryonic stem (es) cell system
CA2558946C (en) 2003-07-08 2013-05-21 Axiogenesis Ag Novel method for the preparation of embryoid bodies (ebs) and uses thereof
ATE508183T1 (de) 2003-07-08 2011-05-15 Axiogenesis Ag Sekretierte proteine für zelldifferenzierungsmarker
US7452718B2 (en) 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
ES2701704T3 (es) * 2004-04-07 2019-02-25 Ncardia Ag Sistemas de ensayo tisulares funcionales no invasivos in vitro
ES2770067T3 (es) 2004-05-11 2020-06-30 Ncardia Ag Descubrimiento de fármacos basado en células diferenciadas in vitro
CN103113463B (zh) 2005-12-13 2015-02-18 国立大学法人京都大学 核重新编程因子

Also Published As

Publication number Publication date
EP1740945A1 (en) 2007-01-10
US9945840B2 (en) 2018-04-17
US20180299426A1 (en) 2018-10-18
US20080132422A1 (en) 2008-06-05
WO2005098425A1 (en) 2005-10-20
ES2701704T3 (es) 2019-02-25
US11835433B2 (en) 2023-12-05
JP5074921B2 (ja) 2012-11-14
CA2560334A1 (en) 2005-10-20
JP2007532103A (ja) 2007-11-15
US20210025869A1 (en) 2021-01-28
EP1740945B1 (en) 2018-09-19

Similar Documents

Publication Publication Date Title
US11835433B2 (en) Non-invasive, in vitro functional tissue assay systems
US20230160877A1 (en) Assay for drug discovery based on in vitro differentiated cells
EP1644486B1 (en) NOVEL METHOD FOR THE PREPARATION OF EMBRYOID BODIES (EBs) AND USES THEREOF
US20170160259A1 (en) Tissue modeling in embryonic stem (es) cell system
US20090328243A1 (en) Secreted proteins as markers for cell differentiation